Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02812420 |
| Title | Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Neoadjuvant Chemotherapy |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | M.D. Anderson Cancer Center |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA |